– With five approved vaccines, it has a diverse portfolio, based both on novel technologies such as mRNA and classic technologies such as Novavax, which is based on proteins. Vaccinations and booster doses are our best protection against COVID-19, assessed Ursula von der Leyen.
Studies have shown approximately 90 percent effectiveness
Previously, After Thorough (EMA) concluded that the vaccine data was reliable and met EU criteria for efficacy, safety and quality.
The results of two main clinical trials showed that Nuvaxovid was effective in prevention in people aged 18 years and over. A total of over 45,000 people participated in the research. people. In the first study, about two-thirds of the participants received a placebo injection and the remainder; in the second study, participants were equally divided between Nuvaxovid and placebo. People didn’t know if they had been given Nuvaxovid or a placebo.
More information from the world at.
The first study, conducted in Mexico, showed 90.4 percent. vaccine efficacy. The second UK study also found a similar reduction in symptomatic COVID-19 cases in people who received Nuvaxovid (10 out of 7020 people) compared to those given a placebo (96 out of 7019 people); in this study, vaccine effectiveness was 89.7%.
‘The results from both indicate that the vaccine efficacy for Nuvaxovid is approximately 90%. The primary SARS-CoV-2 strain and some of the variants of concern such as alpha and beta were the most common viral strains circulating during the studies. Limited efficacy data are currently available. of Nuvaxovid against other variants of concern, including omicron, ‘the EMA said.
Mild and moderate side effects
The side effects seen with Nuvaxovid in the studies were usually mild to moderate and disappeared within a few days after vaccination. The most common of these are injection site pain, fatigue, muscle aches, headache, general malaise, joint pain, and nausea or vomiting.
‘The safety and effectiveness of the vaccine will continue to be monitored as it is used across the EU through the EU pharmacovigilance system and additional studies by the company and European authorities,’ the EMA said.
***
Coronavirus: all current information and recommendations on
Source: Gazeta
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
